Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors
Version of Record online: 24 FEB 2011
© 2011 Japanese Cancer Association
Volume 102, Issue 4, pages 883–889, April 2011
How to Cite
Setoguchi, T., Kikuchi, H., Yamamoto, M., Baba, M., Ohta, M., Kamiya, K., Tanaka, T., Baba, S., Goto-Inoue, N., Setou, M., Sasaki, T., Mori, H., Sugimura, H. and Konno, H. (2011), Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors. Cancer Science, 102: 883–889. doi: 10.1111/j.1349-7006.2011.01872.x
- Issue online: 18 MAR 2011
- Version of Record online: 24 FEB 2011
- Accepted manuscript online: 18 JAN 2011 02:06PM EST
- (Received November 8, 2010/Revised January 6, 2011/Accepted January 8, 2011/Accepted manuscript online January 18, 2011)
Fig. S1. Representative immunohistochemical staining for versican in gastric GIST.
Fig. S2. Representative immunohistochemical staining for CD9 in gastric GIST.
Fig. S3. Versican and CD9 expressions in primary intestinal GIST and in patients’ prognosis.
Table S1. RT-PCR primers.
Table S2. Downregulated and upregulated genes in metastatic liver tumors.
Table S3. Gene ontology.
Table S4. Clinicopathological features of primary intestinal GIST and metastatic liver GIST.
Table S5. Relationship between clinicopathological factors and postoperative disease-free survival in 29 intestinal GIST patients.
|CAS_1872_sm_FigsS1-3.pdf||446K||Supporting info item|
|CAS_1872_sm_TablesS1-5.xls||119K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.